Holen Sie sich die Stockscreener-App
23.77
34.98%
6.16
Handel nachbörslich:
23.57
-0.20
-0.84%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast - Benzinga
Sarepta Stock Surges 30% After Gene Therapy Trials. The Safety Debate Is Far From Over. - Barron's
Traders Purchase Large Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT) - MarketBeat
Market movers: Sarepta Therapeutics, Chewy, Merck, Cognyte Software… - Proactive financial news
Wednesday's session: top gainers and losers - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sarepta Therapeutics (SRPT) Stock Climbs Following Positive siRNA Muscular Dystrophy Trial Results - MEXC
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1Slideshow (NASDAQ:SRPT) 2026-03-25 - Seeking Alpha
Sarepta Stock Surges 29% After Gene Therapy Trials. The Safety Debate Is Far From Over. - Barron's
Sarepta (SRPT) Sees Promising Phase 1/2 Results in Neuromuscular Treatment - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap UpTime to Buy? - MarketBeat
Sarepta sees early success with RNAi drugs from Arrowhead - BioPharma Dive
Sarepta Therapeutics’ experimental siRNA therapies show promising early results - Proactive financial news
Which stocks are gapping on Wednesday? - ChartMill
Why Is Sarepta Therapeutics Stock Exploding Today? - Benzinga
Sarepta Therapeutics (SRPT) Surges 25% on Promising Trial Data - GuruFocus
SRPT: SRP-1001 and SRP-1003 show potent gene knockdown and safety, advancing toward phase III trials - TradingView
Sarepta (SRPT) Reveals Mixed Results in siRNA Programs for Neuro - GuruFocus
Sarepta Therapeutics shares rise on early promise for rare disease drugs - statnews.com
Sarepta (SRPT) Stock: Rises on Early siRNA Trial Data for Muscular Dystrophy Programs - CoinCentral
Sarepta posts data for muscular dystrophy drugs (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? - 24/7 Wall St.
Sarepta stock surges 14% on early siRNA trial data By Investing.com - Investing.com Canada
Sarepta shares early trial data for two rare disease therapies - Investing.com
SRPT Stock Rallies After Promising Early Results For RNA Therapies Targeting Rare Muscle Diseases - Stocktwits
Sarepta announces first clinical data from sirna pipeline targeting FSHD1 and DM1 - marketscreener.com
Sarepta shares early clinical data from siRNA treatments for rare diseases - StreetInsider
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics
Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP - Law360
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Sarepta Therapeutics
Sarepta plans to seek full FDA approval of 2 Duchenne treatments - Muscular Dystrophy News
Sarepta Therapeutics: A $2B Business Priced Like It’s Broken (NASDAQ:SRPT) - Seeking Alpha
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares - BioPharma Dive
Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo! Finance Canada
How FDA Review of Sarepta’s ESSENCE Data At Sarepta Therapeutics (SRPT) Has Changed Its Investment Story - Yahoo Finance
Sarepta to soon submit SNDAs for traditional approval for Duchenne treatments - MSN
SRPT Stock Price, Quote & Chart | SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) - ChartMill
SRPT stock up as enrollment begins in DMD gene therapy safety study - MSN
Sarepta to request FDA for traditional approvals for Duchenne drugs - MSN
Sarepta plans FDA filings seeking full approval for two DMD therapies - MSN
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies - Yahoo Finance
Neuromuscular Disease Therapeutics Market to Reach US$45.62 - openPR.com
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
MDA 2026: ‘Body of evidence for Elevidys continues to grow’ - Muscular Dystrophy News
Sarepta’s Plans To Seek Traditional Approval For DMD Therapies ‘Positive,’ Says Wall Street Analyst - Stocktwits
Sarepta cleared to re-submit sNDAs for Amondys and Vyondys - The Pharma Letter
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
Sarepta (SRPT) sNDA Filing Indicates Positive Outlook - GuruFocus
Oppenheimer Reiterates "Outperform" Rating for Sarepta Therapeutics (SRPT) | SRPT Stock News - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Earns Outperform Rating from Oppenheimer - MarketBeat
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure - BioSpace
Sarepta plans FDA filing for DMD drug approvals by end of April - Investing.com
Sarepta (SRPT) Plans sNDA Submissions for Duchenne Therapies - GuruFocus
Sarepta plans regulatory submissions for two Duchenne drugs by April 2026 - StreetInsider
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® - itemonline.com
How Investors Are Reacting To Sarepta Therapeutics (SRPT) Pushing Duchenne Drugs Toward Full FDA Approval - Sahm
KROS: Is the Discount Book Value a Value Trap? - TradingView
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study - TradingView
Arrowhead Pharmaceuticals earns $100M milestone from Sarepta Therapeutics - MSN
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - BioSpace
Sarepta (SRPT) Advances ENDEAVOR Study with New Cohort - GuruFocus
Sarepta announces that screening and enrollment are underway in Endeavor cohort 8 to evaluate enhanced immunosuppression regimen as part of Elevidys gene therapy for non-ambulant individuals with Duchenne - marketscreener.com
Sarepta begins trial testing sirolimus with gene therapy - Investing.com
Sarepta begins enrollment for enhanced safety protocol in gene therapy study - StreetInsider
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):